24.09 2018 . 52,1 .

alt Evaluate Pharma, (Compound Annual Growth Rate) 20132018 . 4%. , 2018 . 52,1 . .

, Evaluate Pharma, .

IMS Health, 2012 . : Humira (; Abbott Laboratories), Enbrel (; Amgen Pfizer) Remicade (; Johnson&Johnson, Merck&Co. Mitsubishi Tanabe Pharma). 8,5 ., 7,5 . 7,3 . .

Evaluate Pharma, 2018 . , Humira, , 2018 . 23,5% (12,8 .).

. Xeljanz (; Pfizer), 2018 . 2,7 .

www.fiercepharma.com; www.imshealth.com